Pharmacokinetic and Dose Tolerability Study of ADD 94057 in Comedicated Patients with Partial Seizures

Gordon W. Pledger, Kenneth D. Laxer, J. Todd Sahlroot, M. Robin Taylor, James J. Cereghino, Cynthia McCormick, Lois Whitley, Linda W. Manning

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Summary: ADD 94057, a metabolite of fluzinamide, manufactured by the A. H. Robins Company, blocks chemically‐ and electrically‐induced seizures in animals. The primary objective of this open add‐on study was to evaluate patient tolerability of ADD 94057 at ascending target plasma concentrations. Nine subjects with medically refractory seizures were receiving phenytoin (PHT, 3), carbamazepine (CBZ, 3), or both (3). A pharmacokinetic profile after a single oral 400‐mg dose of ADD 94057 was used to calculate ADD 94057 dosages. After a 4‐week baseline period, patients were treated for 4 weeks with weekly ADD 94057 dosage escalations. Two patients completed the study at their assigned highest dosage level; the other patients finished the study at lower dosages. The patients receiving PHT (but not CBZ) tolerated higher plasma concentrations of ADD 94057 than did patients receiving CBZ, alone or in combination with PHT. Adverse experiences included headache, ataxia, blurred vision, diplopia, dizziness, lightheadedness, and mild confusion. Eight of nine patients had reductions in seizure frequency from baseline.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
Issue number1
StatePublished - Jan 1992
Externally publishedYes


  • Antiepileptic drugs
  • Clinical trial
  • Drug dose
  • Epilepsy
  • Partial seizures
  • response relationship

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Pharmacokinetic and Dose Tolerability Study of ADD 94057 in Comedicated Patients with Partial Seizures'. Together they form a unique fingerprint.

Cite this